Arbor Biotechnologies, Inc.

35 articles with Arbor Biotechnologies, Inc.

• 

  Vertex Leans into Gene Editing Space with Extended Arbor Pact

  1/12/2023

  Vertex and Arbor Biotechnologies extend partnership in precision gene editing.

• Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase

  1/11/2023

  Arbor Biotechnologies (Arbor) today announced the expansion of an existing strategic collaboration covering in vivo genetic medicines by which Vertex Pharmaceuticals Incorporated (Vertex) will receive rights to Arbor’s novel precision editing technology for up to three diseases.

• Arbor Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Arbor Biotechnologies will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT.

• Arbor Biotechnologies’ CEO Devyn Smith, Ph.D., Elected as Chairman of the Alliance for Regenerative Medicine

  10/20/2022

  Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that its Chief Executive Officer, Devyn Smith, Ph.D., has been elected as the Chairman of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.

• Arbor Biotechnologies to Participate in the 2022 Cell & Gene Meeting on the Mesa

  10/4/2022

  Arbor Biotechnologies today announced that senior management will participate in a panel discussion and present a corporate overview at the 2022 Cell & Gene Meeting on the Mesa.

• Arbor Biotechnologies to Participate in Upcoming Healthcare Investor Conferences

  9/22/2022

  Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in upcoming healthcare investor conferences in September and October.

• Arbor Biotechnologies Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

  9/12/2022

  Arbor Biotechnologies announced that Fierce Biotech has named it as one of 2022’s “Fierce 15” biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

• Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases

  8/25/2022

  Arbor Biotechnologies today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles (LNP).

• Arbor Biotechnologies Appoints Lee Ann Marchionna as Chief People Officer

  8/2/2022

  Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Lee Ann Marchionna, MBA, to the newly created role of Chief People Officer.

• Arbor Biotechnologies to Present at the Bank of America Global Healthcare Conference

  5/3/2022

  Arbor Biotechnologies today announced its participation in the upcoming Bank of America Global Healthcare Conference in Las Vegas, NV.

• Arbor Biotechnologies Announces Presentations at 2022 Annual Meeting of the American Society of Gene & Cell Therapy

  5/2/2022

  Arbor Biotechnologies announced upcoming preclinical data presentations at the 25th Annual Meeting of the American Society of Gene & Cell Therapy being held May 16-19, 2022, in Washington, D.C.

• Arbor Biotechnologies Appoints Steven J. Favaloro as Chief Financial Officer

  2/22/2022

  Arbor Biotechnologies today announced the appointment of Steven J. Favaloro as Chief Financial Officer.

• 

  Global Roundup: Celltrion Prepares to Trap COVID-19 in Phase III

  2/10/2022

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

• EdiGene and Arbor Biotechnologies Announce Worldwide Non-exclusive License Agreement to Advance Ex Vivo Engineered Cell Therapy Programs

  2/8/2022

  EdiGene, Inc. announced a non-exclusive, worldwide license agreement with Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, to access Arbor’s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology.

• Arbor Biotechnologies to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/10/2022

  Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, announced its participation in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

• TCR² Therapeutics and Arbor Biotechnologies Establish Collaboration to Advance Allogeneic TRuC-T Cell Therapies

  1/4/2022

  TCR2 Therapeutics Inc. (Nasdaq: TCRR), and Arbor Biotechnologies, today announced that the two companies have entered into a strategic research collaboration and non-exclusive license agreement focused on the further development of a defined set of allogeneic TRuC-T cell therapies.

• 

  Money on the Move: November 3 – 9

  11/10/2021

  Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here's who snagged funding this week.
• 

  Arbor Scores $215 Million for Next-Gen CRISPR Toolbox

  11/9/2021

  Arbor announced an oversubscribed Series B raise totaling $215 million, a significant increase from their initial $15.6 milllion Series A round to test for liver and CNS diseases.

• Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics

  11/9/2021

  Arbor Biotechnologies today announced the completion of an oversubscribed and up-sized $215 million Series B financing.

• 

  Vertex and Arbor Strike a $1.2 Billion Deal for Gene-Editing Programs

  8/24/2021

  With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.